A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Part of paid clinical trials in Foxborough, Massachusetts.

Sponsor
Neurology Center of New England P.C.
Study ID
NCT06681623
Status
Recruiting
Apply to this trial

Conditions

  • Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Eligibility Criteria

Sex
ALL
Age
55 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Ublituximab — DRUG
    Drug: ublituximab

Study Details

The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate

Key Dates

Start date
Aug 13, 2024
Status verified
Nov 2024
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

Incidence of infection (including UTI and other active acute, opportunistic and/or chronic infection) [ Time Frame: From Baseline to Month 24/End of Study ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Neurology Center of New England P.C.FoxboroughMassachusetts02035
Rachel ODonnell
[email protected]
781-551-5812
Jillian Pellegrini
[email protected]
781-551-5812
Salvatore Napoli, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Foxborough, MA

By research site
Neurology Center of New England P.C.· Foxborough, MA